New cycler

Outstanding diagnostic performance of the M371 test on new qPCR platforms

mir|detect has the M371-Test for the detection of testicular germ cell tumours has been validated for use on two new qPCR platforms:

  • AriaDx (Agilent)
  • QuantStudio 5 (ThermoFisher Scientific)

 

The M371-Test offers the same excellent diagnostic performance on both devices as on the LightCycler 480 II, increasing accessibility for laboratories and thus the number of patients treated by the M371-Test benefit.

The company continues to work mir|detect working flat out on the validation of the M371-Test on the LightCycler PRO (Roche) and the CFX96 (Bio-Rad) for the M371-Test accessible to many patients and users.

About mir|detect

The mir|detect GmbH based in Bremerhaven, Germany, develops and produces nucleic acid-based in-vitro diagnostics for the early detection and aftercare of cancer. The CE-IVD-certified flagship product, the M371-Testenables the high-precision diagnosis and monitoring of testicular germ cell tumours. Based on the patented and innovative panta|Q® Technology mir|detect is working on a new generation of liquid biopsy tests.

Contact:
mir|detect GmbH
Fischkai 1 - 27572 Bremerhaven
E-Mail: info@mirdetect.deWeb: www.mirdetect.de

Copyright by me|detect & 21HAVN